Douglas S Hawkins1, Abha A Gupta, Erin R Rudzinski. 1. aDepartment of Pediatrics, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington bDivision of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Canada cDepartment of Pathology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to highlight some of the advances in the way we think about rhabdomyosarcoma (RMS). Recent outcome and biological analyses have shifted the risk stratification and treatment paradigms for pediatric RMS. RECENT FINDINGS: The presence or absence of the FOXO1 translocation is one of the most important prognostic factors in RMS. Future clinical studies will incorporate FOXO1 translocation status within risk stratification criteria. Molecular analyses have identified RAS/NF1, hedgehog, IL-4R, and ALK pathway abnormalities as potential therapeutic targets in RMS. Reductions in systemic therapy are possible, although radiation therapy remains essential to prevent local failures in most patients. SUMMARY: Although survival for RMS has not improved in recent years, refinement in risk stratification, further understanding of the biological drivers of the disease, and modifications in treatment intensity have set the stage for the next generation of studies in RMS.
PURPOSE OF REVIEW: The purpose of this review is to highlight some of the advances in the way we think about rhabdomyosarcoma (RMS). Recent outcome and biological analyses have shifted the risk stratification and treatment paradigms for pediatric RMS. RECENT FINDINGS: The presence or absence of the FOXO1 translocation is one of the most important prognostic factors in RMS. Future clinical studies will incorporate FOXO1 translocation status within risk stratification criteria. Molecular analyses have identified RAS/NF1, hedgehog, IL-4R, and ALK pathway abnormalities as potential therapeutic targets in RMS. Reductions in systemic therapy are possible, although radiation therapy remains essential to prevent local failures in most patients. SUMMARY: Although survival for RMS has not improved in recent years, refinement in risk stratification, further understanding of the biological drivers of the disease, and modifications in treatment intensity have set the stage for the next generation of studies in RMS.
Authors: James R Anderson; Frederic G Barr; Douglas S Hawkins; David M Parham; Stephen X Skapek; Timothy J Triche Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544
Authors: David A Rodeberg; James R Anderson; Carola A Arndt; Fernando A Ferrer; Richard Beverly Raney; Meriel E Jenney; Ines B Brecht; Ewa Koscielniak; Modesto Carli; Gianni Bisogno; Odile Oberlin; Annie Rey; Fred Ullrich; Michael C G Stevens; William H Meyer Journal: Int J Cancer Date: 2011-03-01 Impact factor: 7.396
Authors: Brian P Rubin; Koichi Nishijo; Hung-I Harry Chen; Xiaolan Yi; David P Schuetze; Ranadip Pal; Suresh I Prajapati; Jinu Abraham; Benjamin R Arenkiel; Qing-Rong Chen; Sean Davis; Amanda T McCleish; Mario R Capecchi; Joel E Michalek; Lee Ann Zarzabal; Javed Khan; Zhongxin Yu; David M Parham; Frederic G Barr; Paul S Meltzer; Yidong Chen; Charles Keller Journal: Cancer Cell Date: 2011-02-15 Impact factor: 31.743
Authors: Elai Davicioni; James R Anderson; Jonathan D Buckley; William H Meyer; Timothy J Triche Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche Journal: Am J Pathol Date: 2009-01-15 Impact factor: 4.307
Authors: Carola A S Arndt; Julie A Stoner; Douglas S Hawkins; David A Rodeberg; Andrea A Hayes-Jordan; Charles N Paidas; David M Parham; Lisa A Teot; Moody D Wharam; John C Breneman; Sarah S Donaldson; James R Anderson; William H Meyer Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: David A Rodeberg; Julie A Stoner; Andrea Hayes-Jordan; Simon C Kao; Suzanne L Wolden; Steve J Qualman; William H Meyer; Douglas S Hawkins Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth Journal: J Cancer Res Clin Oncol Date: 2014-11-30 Impact factor: 4.553
Authors: Erin R Rudzinski; James R Anderson; Douglas S Hawkins; Stephen X Skapek; David M Parham; Lisa A Teot Journal: Arch Pathol Lab Med Date: 2015-05-19 Impact factor: 5.534
Authors: David A Rodeberg; Moody D Wharam; Elizabeth R Lyden; Julie A Stoner; Kenneth Brown; Suzanne L Wolden; Charles N Paidas; Sarah S Donaldson; Douglas S Hawkins; Sheri L Spunt; Carola A Arndt Journal: Int J Cancer Date: 2014-12-10 Impact factor: 7.396
Authors: Long Wang; Nicole R Hensch; Kathryn Bondra; Prethish Sreenivas; Xiang R Zhao; Jiangfei Chen; Rodrigo Moreno Campos; Kunal Baxi; Angelina V Vaseva; Benjamin D Sunkel; Berkley E Gryder; Silvia Pomella; Benjamin Z Stanton; Siyuan Zheng; Eleanor Y Chen; Rossella Rota; Javed Khan; Peter J Houghton; Myron S Ignatius Journal: Cancer Res Date: 2021-08-30 Impact factor: 12.701
Authors: Emily Greengard; Yael P Mosse; Xiaowei Liu; Charles G Minard; Joel M Reid; Stephan Voss; Keith Wilner; Elizabeth Fox; Frank Balis; Susan M Blaney; Peter C Adamson; Brenda J Weigel Journal: Cancer Chemother Pharmacol Date: 2020-10-23 Impact factor: 3.333
Authors: Austin G Armstrong; Bruce F Kimler; Brigid M Smith; Teresa K Woodruff; Mary Ellen Pavone; Francesca E Duncan Journal: Future Oncol Date: 2018-01-18 Impact factor: 3.404